ESTRELLA IMMUNOPHARMA, INC. Operating Expenses
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Operating Expenses of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. operating expenses for the quarter ending 2026-06-30 was $2.08M, a 62.41% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. operating expenses for the quarter ending 2026-03-31 was $2.29M, a 8.92% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. operating expenses for the quarter ending 2025-12-31 was $613.20K, a 41.61% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. operating expenses for the quarter ending 2025-09-30 was $4.80M, a 42.18% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. operating expenses for fiscal 2025 was $13.06M.
- ESTRELLA IMMUNOPHARMA, INC. operating expenses for fiscal 2024 was $7.31M, a 34.23% decline from fiscal 2023.
- ESTRELLA IMMUNOPHARMA, INC. operating expenses for fiscal 2023 was $11.11M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-13 | $4.27M 10-Q · filed 2026-08-13 | $4.99M derived: sum of 3 quarters · filed 2026-08-13 | $9.79M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.29M 10-Q · filed 2026-05-18 | $2.91M derived: sum of 2 quarters · filed 2026-05-18 | $7.71M derived: sum of 3 quarters · filed 2026-05-18 | $13.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $613.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $5.41M derived: sum of 2 quarters · filed 2026-03-18 | $10.96M derived: sum of 3 quarters · filed 2026-08-13 | $13.06M 10-K · filed 2026-03-18 |
| 2025-09-30 | $4.80M 10-Q · filed 2025-11-12 | $10.35M derived: sum of 2 quarters · filed 2026-08-13 | $12.45M 10-Q · filed 2025-11-12 | $13.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $5.54M 10-Q · filed 2026-08-13 | $7.65M 10-Q · filed 2026-08-13 | $8.70M derived: sum of 3 quarters · filed 2026-08-13 | $12.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.10M 10-Q · filed 2026-05-18 | $3.15M derived: sum of 2 quarters · filed 2026-05-18 | $6.53M derived: sum of 3 quarters · filed 2026-05-18 | $10.48M derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $1.05M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-18 | $4.43M 10-K · filed 2026-03-18 | $8.38M derived: sum of 3 quarters · filed 2026-03-18 | $8.85M derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-09-30 | $3.38M 10-Q · filed 2025-11-12 | $7.33M derived: sum of 2 quarters · filed 2025-11-12 | $7.80M 10-Q · filed 2025-11-12 | $8.82M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $3.95M 10-Q · filed 2025-08-12 | $4.42M 10-Q · filed 2025-08-12 | $5.44M derived: sum of 3 quarters · filed 2025-08-12 | $7.31M 10-KT · filed 2025-03-25 |
| 2024-03-31 | $469.53K 10-Q · filed 2025-05-14 | $1.49M derived: sum of 2 quarters · filed 2025-05-14 | $3.36M 10-Q · filed 2024-05-15 | $6.09M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.02M 10-Q · filed 2024-02-14 | $2.89M 10-Q · filed 2024-02-14 | $5.62M derived: sum of 3 quarters · filed 2024-11-14 | $8.36M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-09-30 | $1.87M 10-Q · filed 2024-11-14 | $4.60M derived: sum of 2 quarters · filed 2024-11-14 | $7.34M derived: sum of 3 quarters · filed 2024-11-14 | $10.10M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-27 | $5.47M derived: sum of 2 quarters · filed 2024-09-27 | $8.23M derived: sum of 3 quarters · filed 2024-09-27 | $11.11M 10-K · filed 2024-09-27 |
| 2023-03-31 | $2.74M 10-Q · filed 2024-05-15 | $5.50M derived: sum of 2 quarters · filed 2024-05-15 | $8.38M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $2.76M 10-Q · filed 2024-02-14 | $5.64M 10-Q · filed 2024-02-14 | ||
| 2022-09-30 | $2.89M 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |